Total Payments
$190,199
2024 Payments
$36,441
Companies
71
Transactions
1,680
Medicare Patients
9,830
Medicare Billing
$642,025
Payment Breakdown by Category
Other$122,759 (64.5%)
Food & Beverage$27,361 (14.4%)
Travel$21,488 (11.3%)
Consulting$16,300 (8.6%)
Research$1,945 (1.0%)
Education$345.86 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $120,156 | 63 | 63.2% |
| Food and Beverage | $27,361 | 1,536 | 14.4% |
| Travel and Lodging | $21,488 | 47 | 11.3% |
| Consulting Fee | $16,300 | 5 | 8.6% |
| Unspecified | $1,945 | 19 | 1.0% |
| Honoraria | $1,500 | 1 | 0.8% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,103 | 1 | 0.6% |
| Education | $345.86 | 8 | 0.2% |
Payments by Type
General
$188,254
1,661 transactions
Research
$1,945
19 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $126,758 | 398 | $0 (2024) |
| ViiV Healthcare Company | $38,187 | 253 | $0 (2024) |
| Napo Pharmaceuticals Inc | $8,625 | 45 | $0 (2024) |
| Theratechnologies Inc. | $1,936 | 22 | $0 (2024) |
| ABBVIE INC. | $1,399 | 81 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,386 | 79 | $0 (2024) |
| Janssen Biotech, Inc. | $1,153 | 130 | $0 (2022) |
| PFIZER INC. | $1,132 | 103 | $0 (2024) |
| Novo Nordisk Inc | $1,032 | 74 | $0 (2024) |
| Allergan, Inc. | $951.04 | 50 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $36,441 | 199 | Gilead Sciences, Inc. ($32,618) |
| 2023 | $15,502 | 231 | Gilead Sciences, Inc. ($10,699) |
| 2022 | $25,695 | 203 | ViiV Healthcare Company ($13,130) |
| 2021 | $26,906 | 170 | ViiV Healthcare Company ($16,205) |
| 2020 | $5,921 | 147 | Gilead Sciences, Inc. ($4,003) |
| 2019 | $44,229 | 307 | Gilead Sciences, Inc. ($34,562) |
| 2018 | $29,567 | 214 | Gilead Sciences, Inc. ($27,064) |
| 2017 | $5,938 | 209 | Gilead Sciences Inc ($3,493) |
All Payment Transactions
1,680 individual payment records from CMS Open Payments — Page 1 of 68
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.17 | General |
| Category: Gastroenterology | ||||||
| 12/19/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $10.99 | General |
| Category: HIV | ||||||
| 12/18/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $26.49 | General |
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $17.04 | General |
| Category: Respiratory | ||||||
| 12/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.17 | General |
| Category: Gastroenterology | ||||||
| 12/18/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $7.64 | General |
| Category: HIV | ||||||
| 12/17/2024 | Napo Pharmaceuticals Inc | Mytesi (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,103.00 | General |
| Category: Infectious Disease | ||||||
| 12/11/2024 | Napo Pharmaceuticals Inc | Mytesi (Drug) | Food and Beverage | Cash or cash equivalent | $19.66 | General |
| Category: Infectious Disease | ||||||
| 12/11/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $5.60 | General |
| 12/10/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $22.71 | General |
| Category: HIV | ||||||
| 12/09/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: PAIN | ||||||
| 12/06/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $21.64 | General |
| Category: NEUROSCIENCE | ||||||
| 12/06/2024 | Napo Pharmaceuticals Inc | Mytesi (Drug) | Food and Beverage | Cash or cash equivalent | $18.51 | General |
| Category: Infectious Disease | ||||||
| 12/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $33.29 | General |
| 12/05/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $25.36 | General |
| Category: HIV | ||||||
| 12/05/2024 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | In-kind items and services | $5.44 | General |
| Category: HIV | ||||||
| 11/26/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $8.96 | General |
| Category: Obesity | ||||||
| 11/21/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $14.82 | General |
| Category: HIV | ||||||
| 11/18/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $21.57 | General |
| Category: UROLOGY | ||||||
| 11/15/2024 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $3,487.90 | General |
| 11/15/2024 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $486.18 | General |
| 11/12/2024 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | In-kind items and services | $16.69 | General |
| Category: HIV | ||||||
| 11/11/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $74.53 | General |
| 11/11/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $5.62 | General |
| Category: PAIN | ||||||
| 11/08/2024 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $4,205.30 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | Gilead Sciences, Inc. | $1,172 | 8 |
| A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY | ViiV Healthcare Company | $671.18 | 8 |
| A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with Multidrug Resistance | Gilead Sciences, Inc. | $102.42 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 2,112 | 3,685 | $615,991 | $148,088 |
| 2022 | 26 | 2,307 | 4,244 | $566,437 | $156,319 |
| 2021 | 30 | 2,832 | 5,462 | $619,965 | $177,420 |
| 2020 | 29 | 2,579 | 5,665 | $640,774 | $160,198 |
Total Patients
9,830
Total Services
19,056
Medicare Billing
$642,025
Procedure Codes
108
All Medicare Procedures & Services
108 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 285 | 800 | $303,695 | $62,366 | 20.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 131 | 208 | $102,003 | $28,220 | 27.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 132 | 132 | $52,242 | $16,905 | 32.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 280 | 832 | $8,611 | $6,980 | 81.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 158 | 176 | $14,978 | $5,269 | 35.2% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 18 | 24 | $19,073 | $5,140 | 26.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 99 | 110 | $31,548 | $5,114 | 16.2% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2023 | 157 | 180 | $12,420 | $3,919 | 31.6% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 153 | 173 | $20,866 | $3,650 | 17.5% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 95 | 203 | $8,398 | $1,924 | 22.9% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 38 | 38 | $5,420 | $1,428 | 26.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 131 | 142 | $8,230 | $1,316 | 16.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 29 | 113 | $7,865 | $1,060 | 13.5% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 42 | 66 | $6,189 | $1,050 | 17.0% |
| 0124A | Adm sarscv2 bvl 30mcg/.3ml a | Office | 2023 | 18 | 19 | $1,881 | $758.48 | 40.3% |
| 90480 | Admn sarscov2 vacc 1 dose | Office | 2023 | 14 | 17 | $1,683 | $678.64 | 40.3% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 22 | 39 | $2,675 | $632.58 | 23.6% |
| 81002 | Urinalysis, manual test | Office | 2023 | 130 | 150 | $1,802 | $508.09 | 28.2% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 16 | 16 | $1,362 | $479.04 | 35.2% |
| 82270 | Stool analysis for blood to screen for colon tumors | Office | 2023 | 92 | 92 | $1,390 | $394.68 | 28.4% |
| 81003 | Automated urinalysis test | Office | 2023 | 42 | 69 | $659.64 | $151.80 | 23.0% |
| 82947 | Blood glucose (sugar) level | Office | 2023 | 16 | 21 | $384.73 | $80.85 | 21.0% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 14 | 65 | $2,616 | $62.94 | 2.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 300 | 999 | $330,158 | $84,002 | 25.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 141 | 141 | $50,044 | $18,190 | 36.3% |
About Dr. David Prelutsky, MD
Dr. David Prelutsky, MD is a Internal Medicine healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/24/2005. The National Provider Identifier (NPI) number assigned to this provider is 1457354276.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Prelutsky, MD has received a total of $190,199 in payments from pharmaceutical and medical device companies, with $36,441 received in 2024. These payments were reported across 1,680 transactions from 71 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($120,156).
As a Medicare-enrolled provider, Prelutsky has provided services to 9,830 Medicare beneficiaries, totaling 19,056 services with total Medicare billing of $642,025. Data is available for 4 years (2020–2023), covering 108 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Saint Louis, MO
- Active Since 05/24/2005
- Last Updated 02/04/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1457354276
Products in Payments
- Biktarvy (Drug) $33,533
- Truvada (Drug) $31,422
- Descovy (Drug) $26,876
- DOVATO (Drug) $20,638
- Mytesi (Drug) $8,625
- Genvoya (Drug) $1,613
- UBRELVY (Drug) $1,207
- ISENTRESS (Drug) $604.54
- APRETUDE (Biological) $584.25
- PREZCOBIX (Drug) $536.12
- VRAYLAR (Drug) $528.92
- XIFAXAN (Drug) $464.67
- PIFELTRO (Drug) $452.24
- Ozempic (Drug) $422.14
- EGRIFTA (Drug) $409.85
- SYMTUZA (Drug) $409.39
- TRIUMEQ (Drug) $398.20
- JULUCA (Drug) $392.20
- Symtuza (Drug) $392.08
- CABENUVA (Biological) $331.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Saint Louis
Dr. John Lasala, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M
Dr. Mark Fesler, Md, MD
Internal Medicine — Payments: $700,896
Internal Medicine $700,896
Dr. Katie Schroeder, Md, MD
Internal Medicine — Payments: $659,683
Internal Medicine $659,683
Edward Charbek, Md, MD
Internal Medicine — Payments: $260,967
Internal Medicine $260,967
Dr. Michael Reschak, M.d, M.D
Internal Medicine — Payments: $245,910
Internal Medicine $245,910
Dr. Osler Jay Guzon, Md, MD
Internal Medicine — Payments: $237,841
Internal Medicine $237,841